Catalent has entered into a strategic collaboration with Galapagos NV, a biotechnology company with operations in the U.S. and Europe, to support decentralised manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications.

Under the terms of the agreement, Catalent’s commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing for Galapagos’ upcoming trials in New Jersey, New York, and surrounding areas.